Terns reports 64% MMR rate in Phase 1 CARDINAL trial of TERN-701 in CML; selects 320/500 mg RP2D

Terns Pharmaceuticals, Inc.

Overall MMR rate of 64% (18/28) achieved by 24 weeks; cumulative MMR rate 74% (28/38).
At doses >=320 mg QD (RP2D), MMR achievement 75% (18/24) by 24 weeks; DMR rate 36% (10/28).
Safety: 87% patients on treatment; no DLTs; low Grade 3+ cytopenia (<10%); common TEAEs diarrhea, headache, nausea.
Enrollment surpassed 85 patients; company plans pivotal Phase 3 trials in 2L+ and 1L CML in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.